Novartis ($NVS) will pour half a billion dollars into building a biologics manufacturing center in Singapore as its pipeline of drugs fills up with treatments based on biologics. It joins a growing number of drugmakers and contract manufacturers that see drugs based on cell cultures as one of the best bets of the future. The company said today that work will begin early next year and is slated to be complete by 2016. Story